Sotera Health (SHC) Q3 2024 Earnings Transcript

Sotera Health posted Q3 revenue of $285 million, up 8.5% year over year, with adjusted EBITDA up 9% to $146 million and adjusted EPS rising to $0.17 from $0.16, while net income improved to $17 million from a $14 million loss. Management reaffirmed full-year revenue and adjusted EBITDA growth of 4%-6%, but lowered 2024 CapEx guidance to $175 million-$185 million due to timing shifts in Nordion cobalt projects and vendor delays. Segment performance was mixed: Sterigenics growth was steady, Nordion benefited from shipment timing, and Nelson Labs margin improved, though expert advisory services are expected to weigh on Q4 revenue.

Analysis

The setup is better than the headline suggests: SHC is quietly shifting from a “volume recovery” story to a mix-and-price story with improving operating leverage. The key second-order effect is that moderation in Nelson’s advisory line should mechanically improve consolidated quality of earnings over the next 1-2 quarters, even if top-line growth slows, because lower-margin revenue is rolling off while core testing and pricing hold in better-margin businesses. That also means the market may be underestimating how resilient EBITDA can look in Q4 despite softer reported revenue.

The more important bull case is balance-sheet optionality. With leverage already inside the target band and capex stepping down from timing, free cash flow inflects earlier than consensus likely models, which matters because the market has tended to handicap SHC as a litigation/capex overhang rather than a cash generator. If management shows on Investor Day that 2025 peak capex is transitory and the 2026-27 slope is down, the equity should re-rate on FCF yield more than on reported EPS.

The main risk is that investors anchor on the Q4 Nelson guide and miss the offset from Sterigenics pricing and Nordion mix normalization. Near term, that creates a setup for a disappointingly good quarter: headline growth can decelerate while underlying margin durability improves, which often triggers a weak reaction if the street is focused on revenue beats/misses rather than mix. The litigation clock is the real left-tail; any adverse tone ahead of early-2025 Georgia rulings could cap multiple expansion even if fundamentals continue to improve.

Consensus appears too complacent on the long-duration cobalt story and too skeptical on the near-term cash conversion story. Darlington is not a 2028 revenue event, but it does de-risk future supply and supports Nordion’s strategic moat, which should lower perceived execution risk across the portfolio. The tradeable point is that SHC can look like a low-growth healthcare processor today while actually becoming a more durable cash compounder over the next 12-24 months.

Key Decisions for Investors

• Long SHC into the Nov. 20 Investor Day, with a 2-6 week horizon: use any post-earnings/guide-related weakness to build a position ahead of likely FCF and capex disclosure. Risk/reward skews positive if management validates 2025 peak capex and 2026-27 deleveraging.
• Pair trade: long SHC / short a litigation-and-capex-overhang healthcare name over the next 1-3 months. SHC has the cleaner path to FCF inflection; the short leg should be a company with similar regulatory noise but no near-term cash conversion catalyst.
• Buy SHC Jan-2025 or Mar-2025 call spreads on weakness. The catalyst stack is dense: Investor Day, early-2025 Georgia rulings, and ongoing margin normalization in Nelson. Defined-risk upside makes sense if the market is underpricing multiple expansion on better quality of earnings.
• If already long, hedge with a tactical trim or short-dated put spread into Q4/Q1 litigation dates. The left-tail is not operating performance; it is headline risk from Georgia/NESHAP that can suppress multiple expansion even if results stay constructive.
• Add exposure on any pullback below the post-earnings range, but only if Nordion and capex commentary remain intact. The trade breaks if management signals another delay in cobalt monetization or if Nelson’s core testing momentum stalls for more than one quarter.